These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 17659436

  • 1. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare.
    Tian S, Li J, Wang L, Liu T, Liu H, Cheng G, Liu D, Deng Y, Gou R, Wan Y, Jia J, Chen C.
    Inflamm Res; 2007 Jul; 56(7):304-10. PubMed ID: 17659436
    [Abstract] [Full Text] [Related]

  • 2. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 3. Urinary TWEAK and the activity of lupus nephritis.
    Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C.
    J Autoimmun; 2006 Dec; 27(4):242-50. PubMed ID: 17257812
    [Abstract] [Full Text] [Related]

  • 4. Messenger RNA expression of RANTES in the urinary sediment of patients with lupus nephritis.
    Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC.
    Nephrology (Carlton); 2006 Jun; 11(3):219-25. PubMed ID: 16756635
    [Abstract] [Full Text] [Related]

  • 5. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare.
    Singh RG, Usha, Rathore SS, Behura SK, Singh NK.
    Lupus; 2012 Oct; 21(11):1214-8. PubMed ID: 22759858
    [Abstract] [Full Text] [Related]

  • 6. Urine chemokines as biomarkers of human systemic lupus erythematosus activity.
    Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN.
    J Am Soc Nephrol; 2005 Feb; 16(2):467-73. PubMed ID: 15601744
    [Abstract] [Full Text] [Related]

  • 7. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis.
    Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A.
    Lab Invest; 1995 Dec; 73(6):804-9. PubMed ID: 8558841
    [Abstract] [Full Text] [Related]

  • 8. Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis.
    Abujam B, Cheekatla S, Aggarwal A.
    Lupus; 2013 May; 22(6):614-23. PubMed ID: 23629827
    [Abstract] [Full Text] [Related]

  • 9. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis.
    Alzawawy A, Zohary M, Ablordiny M, Eldalie M.
    Int J Rheum Dis; 2009 Dec; 12(4):311-8. PubMed ID: 20374368
    [Abstract] [Full Text] [Related]

  • 10. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
    Mok CC, Ho CT, Chan KW, Lau CS, Wong RW.
    Arthritis Rheum; 2002 Apr; 46(4):1003-13. PubMed ID: 11953978
    [Abstract] [Full Text] [Related]

  • 11. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 12. The long-term outcome of 93 patients with proliferative lupus nephritis.
    Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C.
    Nephrol Dial Transplant; 2007 Sep; 22(9):2531-9. PubMed ID: 17510096
    [Abstract] [Full Text] [Related]

  • 13. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele.
    Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, Hackshaw KV, Yu CY, Malarkey WB, Hebert LA.
    Arthritis Rheum; 2006 Oct; 54(10):3291-9. PubMed ID: 17009264
    [Abstract] [Full Text] [Related]

  • 14. Expression of T-bet, a type 1 T-helper cell transcription factor, in the urinary sediment of lupus patients predicts disease flare.
    Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC.
    Rheumatology (Oxford); 2007 Jan; 46(1):44-8. PubMed ID: 16754628
    [Abstract] [Full Text] [Related]

  • 15. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.
    Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, Ponticelli C.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1541-8. PubMed ID: 16455674
    [Abstract] [Full Text] [Related]

  • 16. The significant role of RANTES and CCR5 in progressive tubulointerstitial lesions in lupus nephropathy.
    Stasikowska O, Danilewicz M, Wagrowska-Danilewicz M.
    Pol J Pathol; 2007 Jun; 58(1):35-40. PubMed ID: 17585540
    [Abstract] [Full Text] [Related]

  • 17. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis.
    Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, Tavoni A, Bombardieri S.
    Kidney Int; 2002 Apr; 61(4):1502-9. PubMed ID: 11918758
    [Abstract] [Full Text] [Related]

  • 18. Urinary biomarkers in lupus nephritis.
    Li Y, Tucci M, Narain S, Barnes EV, Sobel ES, Segal MS, Richards HB.
    Autoimmun Rev; 2006 Jul; 5(6):383-8. PubMed ID: 16890891
    [Abstract] [Full Text] [Related]

  • 19. Biomarker discovery in human SLE nephritis.
    Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA.
    Bull NYU Hosp Jt Dis; 2007 Jul; 65(3):187-93. PubMed ID: 17922668
    [Abstract] [Full Text] [Related]

  • 20. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
    Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.